Skip to main content
Skip to main content
Go to homepage

ADVL1411 Temozolomide in Children with Refractory or Recurrent Malignancies

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

Description:

This study being completed in collaboration with Cincinnati Children's Hospital. For complete information please visit clinicaltrials.gov

Study Status:
Closed
IRB Study ID:
141003
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Stem Cell Transplantation & Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program